CRRT: Current effective delivered dose monitoring for continuous renal replacement therapy
The problem
“dose”: the amount of blood cleared of waste products and toxins by an extracorporeal device per unit of time.
In clinical practice there is a DYNAMIC and UNPREDICTABLE hemodiafilter degradation: clottering and concentration polarization will contribute to the impairment of filter function
delivered dose is LOWER than prescribed dose BY 20-30%
dose under-treatment
higer mortality rate
The solution: A system for the automatic and frequent monitoring of delivered dose in CRRT treatments
In collaboration with:
PATENT: “Current effective delivered dose monitoring for continuous renal replacement therapy” (Original title: “Metodo per acquisire campioni biologici liquidi da un circuito extracorporeo per un trattamento di purificazione ematica extracorporea e relativi apparato e sistema”), Italian Patent Application N. IT102021000032621 of 24th December 2021. Inventors: V Cauda, A. Ancona, G. Villa, S. Romagnoli, Z. Ricci. PCT: WO2023119085 of 29th June 2023. At present: in national phases.
PAPERS
This project has received the following funding:
2022 PoC INSTRUMENT from LiFTT Funding (Duration: 9 months, May 2022 – Feb 2023) – Status: ENDED
2023 PoC Transition – Linea 2 from LifTT funding (Follow-on project to the previous 2022 PoC Instrument, Duration: 12 months, Sep 2023 – Sep 2024) – Status: RUNNING
2023 Poc BiMeC from the Italian Minister of Economical Development (MISE) (Duration: 15 months, Oct 2023 – Dec 2025) – Status: RUNNING
2022 PRIN – Italian Minister of University and Research (MUR), project title “Precision medicine in renal replacement therapy for critically ill patients” Project N. 2022XTBJ55, (Duration: 36 months, Nov 2023 – Oct 2026) – Status: RUNNING
2023 “Monitor CRRT” – funded by Aosta Valley Region, Project N. ICO.01101.23AE.00005 ( Duration: 18 months, Jan 2024 – June 2025) – Status: RUNNING